Clinical trials: Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Refractory Reflux Esophagitis
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
- Trial name
- NCT00770913
- Testing
- E3810
- Where
- 54 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Eisai Co., Ltd.
Reflux Esophagitis
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
- Trial name
- NCT01860482
- Testing
- Newrabell® Tablet 10mg
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Chong Kun Dang Pharmaceutical